All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsBECKMAN RESEARCH INSTITUTE/CITY OF HOPE

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

Projects attributed to BECKMAN RESEARCH INSTITUTE/CITY OF HOPE within this analysis sample.

In This Analysis
Projects
3
NIH Funding
$3.4M
Projects(3)
ProjectPICategoryFunding
Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy
5R01CA284172-02
QING, KUNBiotools$1.4M
Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer
R01CA266665
WU, ANNA M (contact)Therapeutics$1.3M
Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia
R01CA292596
PICHIORRI, FLAVIATherapeutics$739K
See BECKMAN RESEARCH INSTITUTE/CITY OF HOPE’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.